Compare Cytokinetics Inc (CYTK) vs Procter & Gamble Co (PG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Procter & Gamble Co — how do they compare? Cytokinetics Inc trades at $76.67 (market cap $10.78B), while Procter & Gamble Co trades at $145.25 (market cap $340.39B). The key difference: Procter & Gamble Co is far larger — about 31.6× Cytokinetics Inc's market cap, and Procter & Gamble Co pays a 2.97% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CYTK | PG | |
|---|---|---|
Market Cap | $10.78B | $340.39B |
Sector | Technology | Consumer Staples |
52-Week High | $87.26 | $167.18 |
52-Week Low | $34.31 | $138.10 |
Enterprise Value | $10.88B | $366.23B |
Volume | — | 6,423,436 |
Dividend Yield | — | 2.97% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $76.76, down 5.67% today, with a bearish technical signal and negative profitability metrics. Recent Q2 2026 earnings beat EPS estimates but missed on revenue, while the company's drug Myqorzo shows strong commercial uptake and regulatory approvals in the UK. Cash flow remains negative from operations, offset by financing activities.
The outlook is mixed: strong analyst buy ratings (97%) and a $111.14 price target suggest upside, but high cash burn, competitive pressures, and lack of profitability pose significant risks. Investment appeal hinges on successful drug commercialization and path to profitability.
Procter & Gamble (PG) trades at $146.38, up 0.42% today, with a bearish technical signal but strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 EPS expected at $1.90. Revenue reached $84.28B in 2025, with a net income margin of 18.44% and robust cash flow from operations of $17.82B. Analyst consensus is bullish with a $161.20 price target, though valuation multiples like P/E of 22.12 and P/S of 4.08 are at premiums to peers.
The outlook for PG is positive due to steady earnings growth and dividend reliability, but risks include premium valuation concerns and soft demand headwinds. Investors may find opportunity in its defensive qualities amid market volatility, though near-term upside could be limited by technical resistance and modest revenue growth projections.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Procter & Gamble Co
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →
